TRDA Overview

5AM Venture Management's Exit: The firm completely liquidated its position in Viking Therapeutics, selling 189,593 shares for an estimated net position change of $5.02 million, reducing its stake from 1.9% to zero as of Q3 2025.

Market Performance: As of November 18, 2025, Viking Therapeutics shares were priced at $38.00, down 5.6% year-to-date, underperforming the S&P 500 by 18.7 percentage points.

Investment Perspective: The sale is viewed as a rebalancing strategy rather than a lack of confidence in Viking's drug development, emphasizing the long-term nature of investing in clinical-stage biopharmaceuticals.

Investor Insights: The article highlights that individual investors in development-stage biotech must be patient and resilient, as stock movements are primarily driven by clinical data rather than trading activity.

5AM Venture Management's Exit: The fund sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated $13.33 million, which previously represented 5.12% of its assets.

Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and significantly underperforming the S&P 500.

Risk Management Strategy: The decision to exit the investment is seen as a move to reduce risk amid the stock's poor performance, indicating a shift towards more stable investments.

Clinical Development Focus: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial outcomes and milestones.

Top Stock Picks: Three stocks have been identified as Strong Buys by top Wall Street analysts, each with significant upside potential based on recent ratings.

Entrada Therapeutics (TRDA): This biotech company has a Buy rating from all three top analysts covering it, with a projected upside of approximately 212.5%.

Exodus Movement, Inc. (EXOD): A software company with a Buy rating from all six top analysts, it has a price target of $50 per share, indicating an upside of about 127.8%.

Nurix Therapeutics (NRIX): This biotech firm has a majority Buy rating from top analysts, with a revised price target of $21 per share, suggesting an upside of around 128%.